Chronic Refractory Cough Pipeline Shows Focused Development With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight's, "Chronic Refractory Cough Pipeline Insight 2026" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Chronic Refractory Cough pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Chronic Refractory Cough Pipeline. Dive into DelveInsight's comprehensive report today! @ https://www.delveinsight.com/sample-request/chronic-refractory-cough-pipeline-insight?utm_source=open&utm_medium=pr&utm_campaign=kkpr

Key Takeaways from the Chronic Refractory Cough Pipeline Report

• DelveInsight's Chronic Refractory Cough Pipeline report depicts a focused therapeutic space with 5+ active players working to develop 5+ pipeline therapies for Chronic Refractory Cough treatment.

• The leading Chronic Refractory Cough Companies such as GSK, Hubei Bio-Pharmaceutical Industrial Technological Institute Inc., Trevi Therapeutics and others.

• Promising Chronic Refractory Cough Pipeline Therapies such as Camlipixant, HW091077, Haduvio and others.

Stay ahead with the most recent pipeline outlook for Chronic Refractory Cough. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ https://www.delveinsight.com/sample-request/chronic-refractory-cough-pipeline-insight?utm_source=open&utm_medium=pr&utm_campaign=kkpr

Chronic Refractory Cough Overview

Chronic refractory cough (CRC) is a persistent cough lasting longer than eight weeks that remains unresolved despite thorough evaluation and treatment of underlying causes such as asthma, gastroesophageal reflux disease, or upper airway cough syndrome. It is increasingly recognized as a disorder of cough hypersensitivity, in which heightened sensitivity of airway sensory nerves leads to an exaggerated cough reflex triggered by otherwise innocuous stimuli such as talking, cold air, or mild irritants.

CRC is characterized primarily by a persistent, dry cough lasting more than eight weeks that does not respond to standard treatments for common underlying conditions. Patients often experience frequent coughing bouts triggered by everyday stimuli such as talking, laughing, cold air, strong smells, or eating. A hallmark feature is a heightened cough reflex accompanied by sensations of throat irritation, tickling, or an urge-to-cough feeling (laryngeal paresthesia). Additional symptoms may include hoarseness, throat clearing, and a sensation of something stuck in the throat (globus).

Chronic refractory cough is primarily understood as a disorder of cough hypersensitivity, in which the neural pathways regulating the cough reflex become dysregulated. Repeated airway inflammation or injury-often from prior respiratory conditions-leads to sensitization of peripheral sensory nerves (particularly vagal afferents) in the airway epithelium. This results in an exaggerated response to otherwise harmless stimuli such as talking, cold air, or mild irritants. At the molecular level, upregulation of receptors such as transient receptor potential (TRP) channels and purinergic P2X3 receptors contributes to heightened neuronal excitability.

The etiology of CRC is typically multifactorial and often follows common causes of chronic cough that have either been treated or are no longer active. These include conditions such as asthma, gastroesophageal reflux disease (GERD), upper airway cough syndrome (postnasal drip), and respiratory infections, which may initially trigger the cough reflex. Environmental exposures (e.g., pollutants, smoke), use of medications like ACE inhibitors, and laryngeal dysfunction can also contribute.

The diagnosis of CRC is largely one of exclusion and follows a systematic evaluation of chronic cough lasting more than eight weeks. Clinicians begin with a detailed clinical history, medication review (e.g., ACE inhibitors), and assessment for common underlying causes such as asthma, gastroesophageal reflux disease (GERD), and upper airway cough syndrome. Standard investigations may include chest imaging (X-ray or CT), spirometry or lung function testing, and, when indicated, tests for airway inflammation or reflux. If the cough persists despite appropriate treatment of these conditions and no alternative cause is identified, the diagnosis of CRC is considered.

Chronic Refractory Cough Emerging Drugs Profile

• Camlipixant: GSK

Camlipixant (formerly BLU-5937) is an investigational, oral, small-molecule P2X3 receptor antagonist designed to treat refractory chronic cough (RCC) and other cough hypersensitivity disorders. The P2X3 receptor is an ATP-gated ion channel highly expressed on sensory nerve fibers in the airways, particularly vagal C-fibers and Aδ-fibers that mediate the cough reflex. In chronic refractory cough, these sensory neurons become hypersensitive, responding excessively to normally innocuous stimuli. By selectively antagonizing P2X3 receptors, Camlipixant reduces the hyperexcitability of these sensory neurons, thereby dampening the exaggerated cough reflex without affecting normal protective cough mechanisms.

Phase IIb studies (SOOTHE trial) have demonstrated that Camlipixant effectively reduces 24-hour cough frequency by approximately 34% at both 50-mg and 200-mg doses compared to placebo. Importantly, the drug has shown a favorable safety profile with notably low rates of taste alteration (dysgeusia), a common adverse effect associated with other P2X3 antagonists. This improved tolerability profile may enhance patient compliance and quality of life during long-term treatment. The oral formulation provides convenient once-daily or twice-daily dosing, making it practical for chronic disease management.

Camlipixant represents a targeted, mechanism-based approach to treating CRC by addressing the underlying neuronal hypersensitivity rather than simply suppressing cough through sedation or central nervous system effects. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Chronic Refractory Cough, with the potential to become a first-line therapy for this challenging condition.

• HW091077: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

HW091077 is an investigational therapeutic candidate being developed by Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. for the treatment of chronic refractory cough. While specific mechanistic details have not been fully disclosed publicly, HW091077 represents one of the emerging therapeutic approaches aimed at addressing the underlying pathophysiology of CRC, particularly targeting the cough hypersensitivity pathways that characterize this condition.

The development of HW091077 reflects the growing recognition within the pharmaceutical industry that chronic refractory cough is a distinct neurological disorder requiring targeted intervention beyond traditional cough suppressants. The compound is designed to provide relief for patients who have not responded to conventional therapies for common cough etiologies such as asthma, GERD, or upper airway cough syndrome.

HW091077 is being evaluated in clinical trials to assess its efficacy in reducing cough frequency and severity, as well as improving quality of life measures such as sleep disruption, social embarrassment, and daily functioning impairment caused by persistent coughing. Safety and tolerability profiles are also being carefully monitored throughout the development process. The drug is currently progressing through clinical development stages for chronic refractory cough indication, representing an important addition to the limited therapeutic landscape for this underserved patient population.

• Haduvio: Trevi Therapeutics

Haduvio is an investigational neuromodulator being developed by Trevi Therapeutics for the treatment of chronic refractory cough and other conditions characterized by neuronal hypersensitivity. The therapeutic agent is designed to target the dysregulated neural pathways that underlie the exaggerated cough reflex seen in patients with chronic refractory cough, particularly those who have failed standard treatments for identifiable underlying causes.
Chronic refractory cough is increasingly understood as a neuropathic disorder in which peripheral and central sensitization of cough-related neural pathways leads to heightened responsiveness to normally innocuous stimuli. Haduvio's mechanism appears to modulate these hypersensitive neural circuits, potentially acting on multiple levels of the cough reflex arc-from peripheral sensory nerve terminals in the airways to central processing centers in the brainstem.

The development of Haduvio addresses a significant unmet medical need, as patients with chronic refractory cough often experience substantial impairment in quality of life, including sleep disturbance, social isolation, urinary incontinence, rib fractures, and psychological distress. Current treatment options remain limited, with off-label use of medications such as gabapentin, pregabalin, and low-dose opioids showing variable efficacy and tolerability concerns.

Haduvio is being evaluated in clinical trials to assess its ability to reduce cough frequency, improve cough-related quality of life measures, and demonstrate acceptable safety and tolerability profiles for chronic use. The drug represents part of a new generation of mechanism-based therapies specifically designed for cough hypersensitivity disorders. Currently, Haduvio is progressing through clinical development for chronic refractory cough, offering hope to patients suffering from this debilitating and often socially isolating condition.

Explore groundbreaking therapies and clinical trials in the Chronic Refractory Cough Pipeline @ https://www.delveinsight.com/sample-request/chronic-refractory-cough-pipeline-insight?utm_source=open&utm_medium=pr&utm_campaign=kkpr

The Chronic Refractory Cough Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Refractory Cough with aggregate therapies developed by each company for the same.
• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Refractory Cough Treatment.
• Chronic Refractory Cough Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Refractory Cough Drugs development pipeline based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Refractory Cough market.
Chronic Refractory Cough Companies
GSK, Hubei Bio-Pharmaceutical Industrial Technological Institute Inc., Trevi Therapeutics and others.

Chronic Refractory Cough Products Route of Administration

Chronic Refractory Cough pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been
categorized under various ROAs such as:
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Chronic Refractory Cough Products Molecule Type

Chronic Refractory Cough Products have been categorized under various Molecule types such as:
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Unveil the future of Chronic Refractory Cough Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ https://www.delveinsight.com/sample-request/chronic-refractory-cough-pipeline-insight?utm_source=open&utm_medium=pr&utm_campaign=kkpr

Scope of the Chronic Refractory Cough Pipeline Report

• Coverage- Global
• Chronic Refractory Cough Companies- GSK, Hubei Bio-Pharmaceutical Industrial Technological Institute Inc., Trevi Therapeutics and others.
• Chronic Refractory Cough Pipeline Therapies- Camlipixant, HW091077, Haduvio and others.
• Chronic Refractory Cough Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Chronic Refractory Cough Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Chronic Refractory Cough Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ https://www.delveinsight.com/sample-request/chronic-refractory-cough-pipeline-insight?utm_source=open&utm_medium=pr&utm_campaign=kkpr

Table of Contents

• Introduction
• Executive Summary
• Chronic Refractory Cough: Overview
• Pipeline Therapeutics
• Therapeutic Assessment
• Chronic Refractory Cough - DelveInsight's Analytical Perspective
• Late-Stage Products (Phase III)
• Mid-Stage Products (Phase II)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products
• Inactive Products
• Chronic Refractory Cough Key Companies
• Chronic Refractory Cough Key Products
• Chronic Refractory Cough - Unmet Needs
• Chronic Refractory Cough - Market Drivers and Barriers
• Chronic Refractory Cough - Future Perspectives and Conclusion
• Chronic Refractory Cough Analyst Views
• Appendix

Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: kkumar@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.